Compare GAU & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAU | CSTL |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.0M | 722.8M |
| IPO Year | 2006 | 2019 |
| Metric | GAU | CSTL |
|---|---|---|
| Price | $2.09 | $29.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.08 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 3.1M | 470.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $82.77 | $2.42 |
| Revenue Next Year | $29.09 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $1.66 | $17.72 |
| 52 Week High | $3.62 | $44.28 |
| Indicator | GAU | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 60.34 |
| Support Level | $1.96 | $22.88 |
| Resistance Level | $2.75 | $34.97 |
| Average True Range (ATR) | 0.09 | 1.81 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 82.41 | 65.06 |
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.